GRX - Gabelli Healthcare & WellnessRx Trust

What this means for you

Saba has told the regulator it may push for changes at this fund. That usually means asking the fund to buy back shares at close to the full value of its holdings, to change who runs it, or to close down and pay holders out.

Nothing is required of you now. If the fund itself announces a buy-back or a vote, it appears in the box above with the date by which you would need to act.

Large investors can also sell down and walk away. We show every notice they file, the day it is filed.

Email me if this changes

What happened, and when

1. Aug 28, 2026

   Saba raised its stake to 14.3% (from 13.3%). It has said it may push for changes.

   Original document →

2. March 19, 2026

   A large investor started a fight over the shareholder vote. The meeting is on May 11, 2026.

   Original document →

3. Oct 20, 2025

   Saba raised its stake to 13.3% (from 12.4%). It has said it may push for changes.

   Original document →

4. Oct 2, 2025

   Sit Investment now owns 5.4%, as a passive investor.

   Original document →

5. March 20, 2025

   A large investor started a fight over the shareholder vote. The meeting is on May 12, 2025.

   Original document →

About this fund

• Run by Gabelli Funds, LLC. Part of the Gabelli Fund Complex fund family. As of Dec 31, 2025, from the fund's yearly report. Original document →
• Size: about $153 million of holdings, as of June 30, 2026. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Borrowing: the fund borrows about 33% on top of its own money, as of June 30, 2026. Borrowed money makes gains and losses bigger. About 92% of that is money the fund has borrowed by selling preferred shares. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• Costs: 1.3% a year in management fees; 3.2% a year in total, including interest on borrowed money. Fiscal year ended Dec 31, 2025. As of Dec 31, 2025, from the fund's yearly report. Original document →
• Payouts: last fiscal year (ended Dec 31, 2025) the fund paid $0.66 a share. $0.06 of that was income; $0.60 came from gains. As of Dec 31, 2025, from the fund's annual report. Original document →
• Value of holdings per share at the last fiscal year end (Dec 31, 2025): $10.53. The shares traded at $9.63, about 8.6% below that. As of Dec 31, 2025, from the fund's yearly report. Original document →
  Over the last two years the gap ranged from 19.3% below to 8.9% below. As of Dec 31, 2025, from the fund's annual report. Original document →
• How the holdings did: up 6.4% over the last three months we have (April-June 2026), before the share price is taken into account. Over the last 12 months: +7.5%. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
• How the holdings did over the fiscal year (ended Dec 31, 2025): the value of the holdings returned +1.7%. How the share price did: the shares returned +6.9% over the same year, counting payouts and the change in the market price. As of Dec 31, 2025, from the fund's annual report. Original document →
• First reported to the regulator in 2007.

What the fund holds

Mostly shares (66%), the rest bonds. About 86% issued in the U.S.

1. United States of America - Bureau of the Public Debt, B 0 09/24/26 - 5.2%
2. United States of America - Bureau of the Public Debt, B 0 12/24/26 - 5.1%
3. United States of America - Bureau of the Public Debt, B 0 07/14/26 - 4.1%
4. United States of America - Bureau of the Public Debt, B 0 10/06/26 - 4.1%
5. Abbvie - 3.9%
6. United States of America - Bureau of the Public Debt, B 0 10/01/26 - 3.7%
7. Merck & Company - 3.7%
8. United States of America - Bureau of the Public Debt, B 0 12/31/26 - 3.6%
9. United States of America - Bureau of the Public Debt, B 0 07/02/26 - 3.5%
10. Teva Pharmaceutical Industries Ltd Sponsored - 2.6%

As of June 30, 2026, from the fund's quarterly holdings report. Original document →